Marc C Chamberlain1, Sandra K Johnston, Alixis Van Horn, Michael J Glantz. 1. Department of Neurology, Division of Neuro-Oncology, University of Washington, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109, USA. chambemc@u.washington.edu
Abstract
BACKGROUND: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). OBJECTIVE: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. DESIGN: Clinical series of 14 patients with CSF positive lymphomatous meningitis. SETTING: Tertiary-care university medical center. RESULTS: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. CONCLUSIONS: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.
BACKGROUND: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). OBJECTIVE: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. DESIGN: Clinical series of 14 patients with CSF positive lymphomatous meningitis. SETTING: Tertiary-care university medical center. RESULTS: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. CONCLUSIONS: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.
Authors: W Boogerd; M J van den Bent; P J Koehler; J J Heimans; J J van der Sande; N K Aaronson; A A M Hart; J Benraadt; Ch J Vecht Journal: Eur J Cancer Date: 2004-12 Impact factor: 9.162
Authors: E L Bollen; R E Brouwer; S Hamers; J Hermans; M Kluin; S U Sankatsing; R V A-Tjak; M V Charvat; J C Kluin-Nelemans Journal: Arch Neurol Date: 1997-07
Authors: C Haioun; C Besson; E Lepage; C Thieblemont; D Simon; C Rose; H Tilly; A Sonet; P Lederlin; M Attal; J Brière; F Reyes Journal: Ann Oncol Date: 2000-06 Impact factor: 32.976
Authors: James L Rubenstein; Jane Fridlyand; Lauren Abrey; Arthur Shen; Jon Karch; Endi Wang; Samar Issa; Lloyd Damon; Michael Prados; Michael McDermott; Joan O'Brien; Chris Haqq; Marc Shuman Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: Sridharan Gururangan; William P Petros; Tina Young Poussaint; Michael L Hancock; Peter C Phillips; Henry S Friedman; Lisa Bomgaars; Susan M Blaney; Larry E Kun; James M Boyett Journal: Clin Cancer Res Date: 2006-03-01 Impact factor: 12.531
Authors: Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle Journal: Neuro Oncol Date: 2014-05-27 Impact factor: 12.300